Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULMGet Rating) in a report issued on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target (up from $5.00) on shares of Pulmatrix in a research report on Wednesday, March 30th.

Shares of Pulmatrix stock opened at $4.58 on Wednesday. The business’s 50 day simple moving average is $5.13 and its 200-day simple moving average is $6.87. Pulmatrix has a twelve month low of $4.03 and a twelve month high of $22.00.

Pulmatrix (NASDAQ:PULMGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The biotechnology company reported ($1.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.10). The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.07 million. Pulmatrix had a negative return on equity of 37.38% and a negative net margin of 426.00%. As a group, research analysts expect that Pulmatrix will post -6.04 EPS for the current year.

An institutional investor recently bought a new position in Pulmatrix stock. Murchinson Ltd. acquired a new position in Pulmatrix, Inc. (NASDAQ:PULMGet Rating) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 100,000 shares of the biotechnology company’s stock, valued at approximately $44,000. Murchinson Ltd. owned approximately 0.18% of Pulmatrix at the end of the most recent reporting period.

Pulmatrix Company Profile (Get Rating)

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Featured Articles

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.